# LRP1B

Source: https://onco.cc/targets/lrp1b/  
OnCo record `lrp1b` (Target). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

LRP1B (Low-density lipoprotein receptor-related protein 1B) is a gene that drives cell growth when it is altered. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Lung cancer, Prostate cancer, Pancreatic ductal adenocarcinoma and 5 more.

## Summary

Potential cell surface proteins that bind and internalise ligands in the process of receptor-mediated endocytosis.

CIViC holds 4 clinical evidence items and 0 assertions across 4 variants, naming Immune Checkpoint Inhibitor and Doxorubicin. Open Targets scores its association with cancer at 0.77 (direct and indirect evidence; datatypes literature 0.97, affected pathway 0.76, genetic association 0.44, somatic mutation 0.88). IntOGen calls it a driver in 70 cohorts (39 activating, 27 loss-of-function), covering Acute Myeloid Leukaemia, Basal Cell Carcinoma, Invasive Breast Carcinoma, Renal Clear Cell Carcinoma, Cholangiocarcinoma, Chronic Lymphocytic Leukaemia/Small Lymphocytic Lymphoma and others.

## Fields

- Kind: Target
- Last checked: 2026-09-23
- Also known as: LDL receptor related protein 1B; Low-density lipoprotein receptor-related protein 1B; LRP-DIT; LRPDIT
- Tags: cancer-genes-wave
- Symbol: LRP1B
- Class: oncogene
- Biology: Potential cell surface proteins that bind and internalise ligands in the process of receptor-mediated endocytosis. Location: Membrane (UniProt). Locus 2q22.1-q22.2 (HGNC).
- Where found: Lung cancer: Open Targets association 0.67 with lung cancer (MONDO_0008903); Prostate cancer: Open Targets association 0.56 with prostate cancer (MONDO_0008315); IntOGen driver in 7 cohorts (PRAD); Pancreatic ductal adenocarcinoma: IntOGen driver in 5 cohorts (PAAD, PANCREAS); Skin cancer: Open Targets association 0.64 with skin cancer (MONDO_0002898); IntOGen driver in 1 cohort (SKIN); Oesophageal cancer: Open Targets association 0.53 with oesophageal cancer (MONDO_0007576); IntOGen driver in 4 cohorts (ESCA); Breast cancer: Open Targets association 0.59 with breast cancer (MONDO_0007254); IntOGen driver in 4 cohorts (BRCA)

## Notes

- Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: CIViC lists 2 therapies; IntOGen calls it an activating (Act) driver in 39 cohorts; IntOGen calls it a loss-of-function (LoF) driver in 27 cohorts; CIViC holds 4 clinical evidence items on its variants. Evidence tier "clinical-evidence" is the strongest of those signals.
- Prevalence not recorded: none of the sources gives a positivity rate.

## Sources

- HGNC HGNC:6693: https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:6693
- UniProt Q9NZR2: https://www.uniprot.org/uniprotkb/Q9NZR2/entry
- NCBI Gene 53353: https://www.ncbi.nlm.nih.gov/gene/53353
- Ensembl ENSG00000168702: https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000168702

## Connected records

- collections: [CIViC](https://onco.cc/collections/civic/), [IntOGen](https://onco.cc/collections/intogen/), [Open Targets Platform](https://onco.cc/collections/open-targets/)
- cancers: [Breast cancer (all types)](https://onco.cc/cancers/breast-cancer/), [Colorectal cancer](https://onco.cc/cancers/colorectal/), [Head and neck squamous cell carcinoma](https://onco.cc/cancers/head-and-neck/), [Lung cancer (all types)](https://onco.cc/cancers/lung-cancer/), [Oesophageal cancer](https://onco.cc/cancers/esophageal/), [Pancreatic ductal adenocarcinoma](https://onco.cc/cancers/pancreatic/), [Prostate cancer](https://onco.cc/cancers/prostate/), [Skin cancer (all types)](https://onco.cc/cancers/skin-cancer/)

---
JSON: https://onco.cc/api/v1/entities/lrp1b.json